2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2016
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors
Hong J, Kwon Y, Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opinion On Drug Metabolism & Toxicology 2016, 13: 183-192. PMID: 27690667, DOI: 10.1080/17425255.2017.1244265.Peer-Reviewed Original ResearchConceptsErectile dysfunctionClinical efficacyEvidence-based clinical efficacyTreatment of EDNon-urological conditionsDrug-related toxicityFirst-line drugsType 5 inhibitorsPhosphodiesterase-5 inhibitorsNew clinical usesChronic administrationBasic science articlesNeuroprotective roleClinical trialsPDE5IsBeneficial effectsClinical usesFurther studiesPharmacodynamicsPharmacokineticsEfficacyInhibitorsImpactful studiesBroad spectrumPDE5i
2015
PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY
Patel N, Salmasi A, Dinizo M, Faiena I, Goyal R, Lee G, Hannan J, Bivalacqua T, Kohn J, Kim I. PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY. Journal Of Urology 2015, 193: e766-e767. DOI: 10.1016/j.juro.2015.02.2255.Peer-Reviewed Original Research
2014
MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY
Patel N, Salmasi A, Dinizo M, Goyal R, Hannan J, Lee G, Kohn J, Bivalacqua T, Kim I. MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY. Journal Of Urology 2014, 191: e481. DOI: 10.1016/j.juro.2014.02.1168.Peer-Reviewed Original Research